The Wei Procedure

Establishing a Globally Recognized Chinese Innovation

Under the leadership of prof Xiang Wei.

The Vass M1 system is suitable for both obstructive and non-obstructive HCM patients requiring surgical intervention. It enables precise septal resection while the heart is still beating—significantly reducing operative risk and trauma, and accelerating recovery.

Clinical Maturity and Global Validation

Since 2019

TA-BSM has evolved from preclinical research to over 1,000 successful clinical cases

with significantly lower postoperative mortality than global averages. Its patented system and top-tier publications provide a strong foundation for international adoption.

Since

2019
1000

successful clinical cases

《Journal of the American College of Cardiology (JACC)》

Global Academic Impact

The Wei Procedure has been featured at major global conferences, drawing significant academic attention and collaboration opportunities.

Selected Conference Highlights:

2025

ASCVTS (Singapore)
AATS (Seattle, USA)
STS (Los Angeles, USA)
2024

EACTS (Lisbon, Portugal)
ASCVTS (Wuhan, China)
AATS (Toronto, Canada)
STS (San Antonio, USA)
2023

EACTS (Vienna, Austria)
ASCVTS (Busan, Korea)

 Professor Wei has delivered invited lectures and surgical demonstrations at leading institutions across the world, including the Mayo Clinic, the Cleveland Clinic, and the Johns Hopkins Hospital, promoting Chinese innovation on a global stage.

Global Training and Visiting Scholars

A comprehensive training platform has been established to support standardization and global dissemination of TA-BSM, attracting visiting surgeons and scholars worldwide.

2023

Dr. Hartzell Schaff (Mayo Clinic, USA) — 2-week visit

2024

Dr. Juan Grau (Valley Health System, USA) — 2-week visit

2024

Dr. Eduardo Quintana & Dr. Cristina (University of Barcelona, Spain) — 1-month intensive training

To Date

Over 20 physicians from 12 countries have participated in our global training program

From innovation to global adoption

TA-BSM has redefined septal reduction therapy and is rapidly gaining international recognition as a new standard in minimally invasive cardiac surgery. Through global academic exchange, strategic IP deployment, and hands-on training, The Wei Procedure exemplifies China's expanding influence in global healthcare innovation.

Global inquiries and collaboration

We welcome physicians, hospitals, and institutions worldwide to contact us for more information about the Wei Procedure (TA-BSM) and the Vass M1 system, or to explore opportunities for training, collaboration, or clinical adoption.